Climb Bio's CLYM116 Shows Favorable Phase 1 Safety, Advancing to Phase 2 in Q3 2026
CLYM has more than doubled off its 52-week low of $1.16.
Summary
Climb Bio presented positive initial Phase 1 safety data and translational modeling results for its drug candidate CLYM116 at the European Renal Association Congress. The data demonstrated a favorable safety profile with no serious adverse events, supporting continued development. This news follows a period of significant positive developments for Climb Bio, including FDA Fast Track designation for another drug and a substantial $110 million private placement. The positive safety data de-risks CLYM116's development, and the company's partner, Mabworks, expects to initiate Phase 2 dosing in IgA nephropathy patients in Q3 2026. Additional PK/PD and updated safety data from Phase 1 studies are expected in late summer.
At the time of this announcement, CLYM was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $624.7M. The 52-week trading range was $1.16 to $12.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.